Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Phase 2a/b study of KVA12123 in mutated NPM1 acute myeloid leukemia patients

Next Previous
Trial Profile

Phase 2a/b study of KVA12123 in mutated NPM1 acute myeloid leukemia patients

Status: Planning
Phase of Trial: Phase II

Latest Information Update: 08 Jul 2025

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs KVA 12123 (Primary)
  • Indications Acute myeloid leukaemia
  • Focus Therapeutic Use

Most Recent Events

  • 30 Jun 2025 According to TuHURA Biosciences media release, TuHURA Biosciences has acquired Kineta. TuHURA is planning to initiate this Phase 2 randomized trial of KVA1213 in combination with a menin inhibitor in NPM1 mutated AML in 2H 2025. The molecule KVA1213 is now renamed as TBS-2025.
  • 03 Jun 2025 According to TuHURA Biosciences media release, Company currently plans to use the net proceeds from the offering to fund cash requirements for the closing the proposed merger with Kineta, Inc. to fund the advancement of Kineta's KVA12123 novel VISTA-inhibiting antibody to a Phase 2 trial, and for other working capital needs.
  • 03 Jun 2025 According to TuHURA Biosciences media release, company announced that it has entered into a definitive securities purchase agreement for the issuance and sale in a private placement of an aggregate of $12.5 million of shares of its common stock, for an aggregate of 4.6 million shares, together with warrants to purchase an equal number shares of common stock at an exercise price of $3.3125 per warrant share.

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top